Abstract
Previously, studies of the endocrine pancreatic β-cell were mainly performed ex vivo by morphological means. This data supported the analyis of pathophysiological changes in the pancreatic islet during insults such as diabetes mellitus. Metabolic testing of the pancreatic islet by assaying hormone parameters such as plasma insulin or C-peptide combined with more or less sophisticated calculations allowed conclusions about states of insulin resistance or secretory failure. It also allowed certain correlations of endocrine function with β-cell mass. Today, with firmer pathophysiological concepts about β-cell failure, modern protocols of islet transplantation, and drugs on the market coming with promises of preservation or even expansion of β-cell mass in diabetes mellitus it has become very attractive to search for tools measuring β-cell mass, if possible even repeatedly in the same organism in vivo. From a clinical point of view, the potential of pancreatic β-cell mass imaging technologies is looked upon with high expectations. Methodologically, the decisive question is whether it is likely that future β-cell imaging will provide significant advantages over the metabolic methods already in hand. With new in vivo tools, studies of β-cell mass and function may offer even new approaches stratifying patients to anti-diabetic therapies.
Keywords: diabetes mellitus, C-peptide, OGTT, pancreatic β-cell
Current Pharmaceutical Design
Title: What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?
Volume: 16 Issue: 14
Author(s): Burkhard Goke
Affiliation:
Keywords: diabetes mellitus, C-peptide, OGTT, pancreatic β-cell
Abstract: Previously, studies of the endocrine pancreatic β-cell were mainly performed ex vivo by morphological means. This data supported the analyis of pathophysiological changes in the pancreatic islet during insults such as diabetes mellitus. Metabolic testing of the pancreatic islet by assaying hormone parameters such as plasma insulin or C-peptide combined with more or less sophisticated calculations allowed conclusions about states of insulin resistance or secretory failure. It also allowed certain correlations of endocrine function with β-cell mass. Today, with firmer pathophysiological concepts about β-cell failure, modern protocols of islet transplantation, and drugs on the market coming with promises of preservation or even expansion of β-cell mass in diabetes mellitus it has become very attractive to search for tools measuring β-cell mass, if possible even repeatedly in the same organism in vivo. From a clinical point of view, the potential of pancreatic β-cell mass imaging technologies is looked upon with high expectations. Methodologically, the decisive question is whether it is likely that future β-cell imaging will provide significant advantages over the metabolic methods already in hand. With new in vivo tools, studies of β-cell mass and function may offer even new approaches stratifying patients to anti-diabetic therapies.
Export Options
About this article
Cite this article as:
Goke Burkhard, What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164081
DOI https://dx.doi.org/10.2174/138161210791164081 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Active Immunization Against Tumor Necrosis Factor-alpha Decreases Proinflammatory Cytokines, Oxidative Stress Mediators and Adhesion Molecules Risk Factors in Streptozotocin-induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology Large Artery Stiffness and Antihypertensive Agents
Current Pharmaceutical Design Autoimmune Hepatitis
Current Pediatric Reviews Advances in Insulin Sensitizers
Current Medicinal Chemistry Editorial:Nutrition Transition in Developing Countries: Focus on South Asia
Current Diabetes Reviews Activation of AMPK by Medicinal Plants and Natural Products: Its Role in Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials
CNS & Neurological Disorders - Drug Targets Formulation Approaches to Overcome Biopharmaceutical Limitations of Inhaled Peptides/Proteins
Current Pharmaceutical Design Cardiovascular Risk Factors: Does Sex Matter?
Current Vascular Pharmacology The Many Roles of Statins in Ischemic Stroke
Current Neuropharmacology Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Imaging of Organ Metabolism in Obesity and Diabetes: Treatment Perspectives
Current Pharmaceutical Design Herbal Natural Products As a Source of Monoamine Oxidase Inhibitors: A Review
Current Topics in Medicinal Chemistry Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research Hypertension, Anti-Hypertensive Therapy and Neoplasia
Current Pharmaceutical Design Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design The Effects of Psychological Stress on Depression
Current Neuropharmacology Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research Oxidative Stress and Endothelial Function: Therapeutic Interventions
Recent Patents on Cardiovascular Drug Discovery